NYSE:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free AIM Stock Alerts $0.42 -0.01 (-2.33%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$0.41▼$0.4450-Day Range$0.33▼$0.6152-Week Range$0.32▼$0.75Volume60,953 shsAverage Volume204,564 shsMarket Capitalization$21.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get AIM ImmunoTech alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode May 20th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About AIM ImmunoTech Stock (NYSE:AIM)AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Read More AIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIM Stock News HeadlinesMay 8, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 30,865 SharesMay 9, 2024 | globenewswire.comAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastMay 9, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.May 6, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®May 6, 2024 | baystreet.caAIM Completes Ampligen TurnoutMay 6, 2024 | globenewswire.comAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®April 29, 2024 | globenewswire.comAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerApril 25, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMay 9, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 15, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsApril 15, 2024 | globenewswire.comAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsApril 11, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentApril 10, 2024 | markets.businessinsider.comAim ImmunoTech Announces Positive Data From Ampligen Study In Combination With PembrolizumabApril 10, 2024 | globenewswire.comAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerApril 5, 2024 | ca.news.yahoo.comNearly 600 cars recovered in sweeping auto theft crackdown in Ontario, Quebec: policeApril 4, 2024 | investing.comEarnings call: AIM ImmunoTech optimistic on Ampligen's future in oncologyApril 3, 2024 | insidermonkey.comAIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comQ4 2023 AIM ImmunoTech Inc Earnings CallApril 2, 2024 | markets.businessinsider.comAIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023April 2, 2024 | globenewswire.comAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comAIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 26, 2024 | globenewswire.comAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastMarch 25, 2024 | globenewswire.comAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchMarch 22, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMarch 20, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMarch 15, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityMarch 9, 2024 | investing.comAIM ImmunoTech launches CEO Corner for direct stakeholder engagementSee More Headlines Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/09/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees26Year Founded1990Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,960,000.00 Net Margins-14,337.62% Pretax Margin-14,337.62% Return on Equity-121.69% Return on Assets-97.91% Debt Debt-to-Equity RatioN/A Current Ratio1.68 Quick Ratio1.68 Sales & Book Value Annual Sales$200,000.00 Price / Sales110.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book2.18Miscellaneous Outstanding Shares50,750,000Free Float50,742,000Market Cap$22.16 million OptionableNot Optionable Beta-0.11 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Thomas K. Equels Esq. (Age 71)J.D., M.S., Executive Vice Chairman, CEO & President Comp: $953.19kMr. Robert Dickey IV (Age 68)M.B.A., Chief Financial Officer Comp: $64.48kMr. Peter W. Rodino III (Age 73)Esq., J.D., COO, Executive Director of Governmental Relations, General Counsel & Secretary Comp: $484.94kAnn Marie E. CoverlyDirector of Administration & Human Resources and Deputy Investor Relations CoordinatorDr. Carol A. Smith (Age 73)Chief Manufacturing Officer & Deputy Chief Scientific Officer Comp: $170.77kDr. Christopher McAleer Ph.D.Scientific OfficerDr. Ralph Christopher Cavalli Ph.D. (Age 66)Vice President of QC & Manufacturing Comp: $234.79kMore ExecutivesKey CompetitorsZIVO BioscienceNASDAQ:ZIVOEvaxion Biotech A/SNASDAQ:EVAXAptose BiosciencesNASDAQ:APTOSenti BiosciencesNASDAQ:SNTIBrainstorm Cell TherapeuticsNASDAQ:BCLIView All CompetitorsInsidersThomas K EquelsBought 61,729 shares on 5/6/2024Total: $25,308.89 ($0.41/share)Peter W Rodino IIIBought 30,865 shares on 5/6/2024Total: $12,654.65 ($0.41/share)Nancy BryanBought 38,462 shares on 3/21/2024Total: $15,000.18 ($0.39/share)Thomas K EquelsBought 75,758 shares on 3/15/2024Total: $25,000.14 ($0.33/share)Stewart AppelrouthBought 90,910 shares on 3/15/2024Total: $30,000.30 ($0.33/share)View All Insider Transactions AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed in 2024? AIM ImmunoTech's stock was trading at $0.4399 at the beginning of 2024. Since then, AIM shares have decreased by 4.5% and is now trading at $0.42. View the best growth stocks for 2024 here. When is AIM ImmunoTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AIM earnings forecast. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) posted its quarterly earnings data on Friday, March, 29th. The company reported ($0.26) earnings per share for the quarter. The business had revenue of $0.07 million for the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 121.69% and a negative net margin of 14,337.62%. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX). How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AIM) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 Media348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.